Moreover, DLGAP5 promotes the proliferation and invasion of hepatocellular carcinoma (HCC) (Tang et al., 2021), bladder cancer (BLCA) (Zhou et al., 2024), and breast cancer (Li et al., 2023). Here, DLGAP5 is linked to bladder transitional cell carcinoma.